These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 20591473)

  • 1. Targeted trials in ovarian cancer.
    Ledermann JA; Raja FA
    Gynecol Oncol; 2010 Oct; 119(1):151-6. PubMed ID: 20591473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The promise and perils of 'targeted therapy' of advanced ovarian cancer.
    Markman M
    Oncology; 2008; 74(1-2):1-6. PubMed ID: 18536523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The future of targeted therapies in ovarian cancer.
    Banerjee S; Gore M
    Oncologist; 2009 Jul; 14(7):706-16. PubMed ID: 19592450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overview of anti-angiogenic agents in development for ovarian cancer.
    Burger RA
    Gynecol Oncol; 2011 Apr; 121(1):230-8. PubMed ID: 21215996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antivascular agents for non-small-cell lung cancer: current status and future directions.
    Amir E; Mandoky L; Blackhall F; Thatcher N; Klepetko W; Ankersmit HJ; Reza Hoda MA; Ostoros G; Dank M; Dome B
    Expert Opin Investig Drugs; 2009 Nov; 18(11):1667-86. PubMed ID: 19877762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New drugs and targeted therapeutic agents in ovarian cancer].
    de La Motte Rouge T; Petrella MC; Michels J; Even C; Balleyguier C; Duclos J; Mazeron R; Morice P; Pautier P; Lhommé C
    Bull Cancer; 2009 Dec; 96(12):1215-24. PubMed ID: 19919916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting signaling pathways in ovarian cancer.
    Reibenwein J; Krainer M
    Expert Opin Ther Targets; 2008 Mar; 12(3):353-65. PubMed ID: 18269344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era.
    Wagner AD; Moehler M
    Curr Opin Oncol; 2009 Jul; 21(4):381-5. PubMed ID: 19412098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic application of noncytotoxic molecular targeted therapy in gliomas: growth factor receptors and angiogenesis inhibitors.
    Idbaih A; Ducray F; Sierra Del Rio M; Hoang-Xuan K; Delattre JY
    Oncologist; 2008 Sep; 13(9):978-92. PubMed ID: 18779539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents.
    Le Tourneau C; Vidal L; Siu LL
    Drug Resist Updat; 2008 Jun; 11(3):99-109. PubMed ID: 18515176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in head and neck cancer therapy: the role of new cytotoxic and molecular-targeted agents.
    Caponigro F; Milano A; Basile M; Ionna F; Iaffaioli RV
    Curr Opin Oncol; 2006 May; 18(3):247-52. PubMed ID: 16552236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cervical cancer therapy: current, future and anti-angiogensis targeted treatment.
    Willmott LJ; Monk BJ
    Expert Rev Anticancer Ther; 2009 Jul; 9(7):895-903. PubMed ID: 19589029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiangiogenic drugs in ovarian cancer.
    Markman M
    Expert Opin Pharmacother; 2009 Oct; 10(14):2269-77. PubMed ID: 19671017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting angiogenesis for the treatment of sarcoma.
    Balasubramanian L; Evens AM
    Curr Opin Oncol; 2006 Jul; 18(4):354-9. PubMed ID: 16721130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Where do antiangiogenic agents belong in the treatment algorithm for ovarian cancer?
    Dizon DS
    Am J Clin Oncol; 2013 Oct; 36(5):519-25. PubMed ID: 21552100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
    Landen CN; Lu C; Han LY; Coffman KT; Bruckheimer E; Halder J; Mangala LS; Merritt WM; Lin YG; Gao C; Schmandt R; Kamat AA; Li Y; Thaker P; Gershenson DM; Parikh NU; Gallick GE; Kinch MS; Sood AK
    J Natl Cancer Inst; 2006 Nov; 98(21):1558-70. PubMed ID: 17077358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New antiangiogenetic agents and non-small cell lung cancer.
    Gridelli C; Rossi A; Maione P
    Crit Rev Oncol Hematol; 2006 Oct; 60(1):76-86. PubMed ID: 16843002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted therapies for non-small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective.
    Raben D; Helfrich B; Bunn PA
    Int J Radiat Oncol Biol Phys; 2004; 59(2 Suppl):27-38. PubMed ID: 15142632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel therapies, including enzastaurin, in the treatment of ovarian cancer.
    Vergote I
    Expert Opin Investig Drugs; 2014 May; 23(5):579-98. PubMed ID: 24654681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.